

San Fu Chemical Co., Ltd.

Minutes for 2026 Annual Shareholders' Meeting

(Translations)

Time and Date: 9:00 a.m., Friday, June 12, 2026

Location: 3F, No.9, Section 1, Nanjing East Road, Taipei City (The Okura Prestige Taipei)

The total outstanding San Fu shares : The total outstanding eligible number of shares is 100,706,000 shares. Of those shares 64.115% or 64,567,277 shares were represented (3,651,199 shares were voted electronically) at the meeting either in person or by a representative for the respective shareholders.

Format : Physical Meeting

Chairman: Wu, Hsin-Hung, the chairman of the Board of Directors

Recorder: Chang Ling-Feng



Meeting process: During the forthcoming Annual Meeting of Shareholders of San Fu Chemical Co., Ltd. an automatic non-stop continuous audio and video recording will be carried out, please watch the real-time online meeting process on our website:

<https://www.sfchem.com.tw/zh-hant/video/index>

Attendance of directors: Wu, Hsin-Hung 、 San Fu Global Ltd. company representative:

Chang, Xi-Wen 、 Tsai, Chieh Jung 、 Su, Tian-Bao 、
Liang, Guo-Yuan ◦

Attendance of independent directors: Hsieh, Yong-Feng 、 Yang, Hong-Zhi ◦

Audit Committee Convenor: Wu, Dong-Ming ◦

I. Chairman of the Meeting announced that the shareholding of shareholders present has met the regulatory requirement so that the Meeting begins.

II. Statement by the Chairman (Omitted)

III. Report Items

Report No. 1:

2025 Business Report

Explanation:

The 2025 Business Report (Attachment 1) ◦

Shareholders were acknowledged.

Report No. 2:

2025 Audit Committee's Report

Explanation:

2025 Audit Committee's Report (Attachment 2)
Shareholders were acknowledged

Report No. 3:

Adoption of the proposal for distribution of 2025 cash dividend

Explanation:

- (1) In accordance with article 28-1 of the Company's Articles of Incorporation, the Board of Directors is authorized to make a special resolution to distribute all or part of the dividends and bonuses in the form of cash and report to the shareholders' meeting.
- (2) The amount of NT\$ 207,454,360 shall be appropriated from the distributable earnings, and cash dividends shall be distributed at NT\$ 2.06 per share. The shareholding ratio of shareholders shall be calculated up to the dollar and the amount less than one dollar distributed to the shareholders shall be transferred to the Company's other income based on the ex dividend base date.
- (3) This proposal was passed by a special resolution of the Board of Directors and authorized the Chairman of the Board of Directors to set another ex dividend base date, issue date and other related matters. If the Company's share capital before the dividend bonus base date changes and affects the total number of outstanding shares, resulting in the change of the shareholder's dividend distribution ratio, the Chairman of the Board of Directors is authorized to make full adjustment.

Shareholders were acknowledged

Report No. 4:

Adoption of the proposal for distribution of 2025 Remuneration of Directors and Supervisors and Remuneration of Employees

Explanation:

- (1) According to the Company's Articles of Incorporation, the amounts allocated for the directors' and employees' remunerations for 2025 are respectively NT\$10,700,000 and NT\$10,700,000, which is distributed in cash.
- (2) The proposal for remuneration of directors, supervisors and employees referred to in the preceding paragraph has been approved by the Company's remuneration committee and the Board of Directors.

Shareholders were acknowledged

Report No. 5:

Adoption of the proposal for applying the International Financial Reporting Standards (IFRS) for adjustments to the Company's distributable surplus and the amount of special surplus reserve transferred.

Explanation:

- (1) Special surplus reserve shall be provided in accordance with letters JGZFZ No. 1010012865 and JGZFZ No. 1010047490 issued by the Financial Supervisory Commission and Questions on the application of special surplus reserve after adoption of international financial reporting standards (IFRSs).
- (2) In accordance with the provisions of the previous circular, the amount of special surplus reserve set aside by the amount of equity deduction as of December 31, 2025 is NT\$37,487,862, so as to let shareholders know the impact of the adjustment of

distributable surplus and the amount of special surplus reserve set forth.
Shareholders were acknowledged

Report No. 6:

Proposal of amendments to the “Rules for Procedure of Board Meetings.”

Explanation:

To comply with legal requirements and operational needs, we propose to amend the Company’s “Rules for Procedure of Board Meetings.” Please see Attachment 4.
Shareholders were acknowledged

Report No. 7:

In connection with the listing (OTC) application by our subsidiary, “SanFu BioPhoenix Co., Ltd.,” we have prepared reports on the status of our share transferred to that company in installments. Please review.

Explanation:

For details regarding the dilution of equity interests in our subsidiary, SanFu BioPhoenix Co., Ltd., please refer to Attachment 5.
Shareholders were acknowledged

IV. Proposals and Resolutions

1.Proposal: Adoption of the 2025 Business Report and Financial Statements

Explanation:

- (1) 2025 Company’s Business Report, Individual Financial Statements and Consolidated Financial Statements, have been approved by the Board of Directors and examined by the supervisors of the Company and were audited by two certified public accountants Vivian Yeh and Leon Huang of independent auditors Deloitte and Touche Taiwan.
- (2) The 2025 Company’s Business Report, Independent Auditor’s Report and the above-mentioned Financial Statements (Attachment 1) and (Attachment 3).
- (3) Please acknowledge.

Voting Results:

Shares represented at the time of voting : 64,567,277 votes

Voting Results*	% of the total represented share present
Votes in favor : 62,174,773votes (1,386,193 votes)	96.29%
Votes against : 6,322 votes (6,322 votes)	0.01%
Votes invalid : none	0.00%
Votes abstained /non-voting : 2,386,182votes	3.70%

(2,258,684 votes)

* : including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby were accepted as submitted.

No proposal is raised by the shareholders at this shareholder meeting.

2.

Proposal: Adoption to the Proposal for Distribution of 2025 Profits

Explanation:

- (1) The Company's after-tax net profit for the year 2025 was NT\$372,318,234, plus actuarial gains and losses included in retained earnings of NT\$607,602, the said amount will be set aside according to the law of statutory surplus reserve of NT\$37,292,584 and reversal the special surplus reserve of NT\$37,487,862. After adding the balance amount to the beginning of the current period accumulated undistributed surplus of NT\$ 2,373,485,236, its total distributable surplus will be NT\$ 2,746,606,350.
- (2) With the approval of the Board of Directors, the aforesaid profit distribution plan for 2025 is hereby formulated as follows:

San Fu Chemical Co. Ltd.	
Proposal for Distribution of 2025 Profits	
Unit: New Taiwan Dollars	
Undistributed surplus at the beginning of the period	2,373,485,236
Add: net profit after tax of the current period	372,318,234
Add: actuarial gains and losses included in retained earnings	607,602
Adjusted undistributed surplus	2,746,411,072
10% statutory surplus reserve	(37,292,584)
Reversal of special surplus reserve	37,487,862
Distributable surplus	2,746,606,350
Distributable Items	
dividend of shareholders (Note)	(207,454,360)
Undistributed surplus at the end of the period	2,539,151,990

Note: Distribution of cash dividend at NT\$2.06 per share is recommended

Chairman:



Manager:



Chief accountant:



Resolution: Shares represented at the time of voting : 64,567,277votes

Voting Results*	% of the total represented share present
Votes in favor : 62,183,373votes (1,394,793votes)	96.31%
Votes against : 6,322 votes (6,322 votes)	0.01%

Votes invalid : none	0.00%
Votes abstained /non-voting : 2,377,582 votes (2,250,084 votes)	3.68%

* : including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby were accepted as submitted.

No proposal is raised by the shareholders at this shareholder meeting.

V. Discussion Items

Proposal 1: (Proposed by the Board of Directors)

Proposal 1: Issue of cash dividends from capital reserve

Explanation:

- (1) It is proposed to allocate NT\$165,157,840 of the capital reserve over the face value of the issued shares to the shares recorded in the shareholders' register on the base date of cash dividend distribution, with NT\$1.64 per share distributed.
- (2) The cash dividends referred to in the preceding paragraph are to be calculated up to NT\$1, and if the amount distributed to the shareholders is less than one dollar shall be transferred to other income of the Company.
- (3) If the total number of outstanding shares is affected by the change of the Company's share capital before the dividend bonus base date, resulting in the change of the shareholder's interest distribution ratio, it is proposed to propose to the shareholders' meeting to authorize the Chairman of the Board of Directors to make adjustment at his discretion.
- (4) The chairman is authorized to decide the record date, distribution date or other related matters of shareholders' dividends after the resolution of the shareholders' meeting is passed.

Resolution: Shares represented at the time of voting : 64,567,277 votes

Voting Results*	% of the total represented share present
Votes in favor : 62,191,003 votes (1,402,423 votes)	96.32%
Votes against : 7,922 votes (7,922 otes)	0.01%
Votes invalid : none	0.00%
Votes abstained /non-voting : 2,368,352votes (2,240,854 votes)	3.67%

* : including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby were accepted as submitted.

No proposal is raised by the shareholders at this shareholder meeting.

Proposal 2: (Proposed by the Board of Directors)

Proposal for amendment of he Company's "Rules of Procedure for Shareholders"

Meetings”. Please make decision after public discussion and voting.

Explanation:

- (1) In order to comply with the provisions of the Financial Regulatory Authority Document No. 1140385797, it is proposed to amend certain provisions of the Company’s “Rules of Procedure for Shareholders’ Meetings” in accordance with Article 6 of the “Regulations Governing Content and Compliance Requirements for Shareholders’ Meeting Agenda of Public Companies” and Article 23 of the “Regulations Governing Information to be Published in Annual Reports of Public Companies”.
- (2) A comparative table of the current and amended articles is available on Attachment 6.

Resolution: Shares represented at the time of voting : 64,567,277 votes

Voting Results*	% of the total represented share present
Votes in favor : 62,166,045 votes (1,377,465votes)	96.28%
Votes against : 28,880 votes (28,880votes)	0.05%
Votes invalid : none	0.00%
Votes abstained /non-voting : 2,372,352votes (2,244,854 votes)	3.67%

* : including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby were accepted as submitted.

No proposal is raised by the shareholders at this shareholder meeting.

g.

VI. Extraordinary Motions : None

VII. Adjournment : Meeting ended at 09:30am

Attachment 1

San Fu Chemical Co., Ltd.

Business Report

Looking back at 2025, driven by easing global interest rate pressures, deepening supply chain restructuring, and the explosive growth of AI applications, economies around the world exhibited structurally divergent growth patterns. However, tariff policies, geopolitical volatility, the impact of extreme weather, the cost pressure of net-zero transition, and the reshaping of industrial competition brought about by generative AI continue to test the resilience and agility of global enterprises. Facing multiple shifts and an uncertain environment, Sanfu Chemical Co., Ltd. leveraged its solid operational foundation and flexible adaptability to continuously drive process optimization, technological innovation, and operational transformation. By strengthening its core competitive advantages, the Company demonstrated corporate resilience and momentum for sustainable development. The following is an overview of the Company's operating results in 2025 and the business plan for 2026:

I. Operating Results of 2025

(1) Business Plan Implementation Results in 2025

1. The Company's achievements in developing new customers and expanding new chemical products and precision chemicals are summarized as follows:

The production situation of the electrolysis plants is summarized as follows: Due to MEA issues in the customer's raw materials, the average lifespan of the electrolytic membranes was reduced to just two months. As a result, Shanhua and Nitto plants frequently had to shut down production to replace the electrolytic membranes, leading to a slight decrease in production line utilization. However, after successful communication with customers, the issue was resolved in the raw materials supplied during the fourth quarter, thereby eliminating the need for production line shutdowns.

Both purification lines at the Nitto Refining Plant are operating stably, with all metal ions in the 25% TMAH finished product consistently maintained below 10 ppt. The facility is currently focused on converting all electrolytically produced TMAH into IC-grade inventory, which not only facilitates data collection but also ensures the ability to meet customer demand at any time.

Last year, the high-purity dilution production line yielded 2.38% of finished products, with the metal concentration in nearly all of them falling below 1 ppt. Although a very small number of tests still show fluctuations in individual metal ions between 1 and 3 ppt, it is estimated that such issues will be significantly reduced once stable, large-scale shipments begin.

In the semiconductor sector, specialty chemicals benefited from the AI boom in 2025. With customers' advanced packaging processes continuing to scale up, new factories being established, and new front-end customers and products gradually ramping up production, the semiconductor division as a whole maintained its pattern of year-over-year revenue growth.

In 2025, the focus was on two major categories of IC chemicals: the first category involves the development of formulation-based products, such as stripping solutions, etching solutions, and cleaning agents; the second category involves the promotion of chemicals for recycling and reuse, such as TMAH and EBR. In addition to these two key

development areas, the approaching timeline for customers' overseas plant construction is expected to become the third growth driver for IC chemicals.

In 2025, the optoelectronic panel industry continued to face challenges due to factors such as insufficient momentum in the global consumer recovery, conservative end-market demand, and intensifying price competition among peers. As a result, the overall market environment remained challenging, leading to a decline in the Company's revenue from panel-related products compared to the previous period. However, the Company continued to deepen its cooperative relationships with key customers. In addition to maintaining stable supply and continuously improving existing chemical products, the Company shifted its operational focus to the specialty gas sector, actively promoting the introduction, validation, and commercialization of related products. By positioning its product portfolio to capture relevant process applications, the Company has laid the foundation for future operational growth and strengthened its overall competitiveness and long-term growth momentum.

The Company's new basic chemical customer development and product line expansion accomplishments are as follows:

Domestic Sales Department: A wide variety of new products have been introduced to sales development for marketing based on the Company's existing customer resources, such as sodium gluconate, sodium bicarbonate, trehalose, anhydrous calcium chloride, oxalic acid, etc. to achieve product diversification. In addition, according to the government's food safety management specifications, a new food additive plant has been built in Liuke plant areas, and the Company is actively developing markets for products with small packaging.

Overseas Sales Department: The market demand of pHBA market remained strong, with the Shanhua Plant operating at full capacity. In addition to existing customers such as the United States, Japan, and China, Japanese clients with factories in Taiwan have already commenced full-scale production and will provide a stable supply to global customers in the future. The Kaohsiung plant will focus its exports on the U.S. market to expand its market share of CHA and DCHA products in the United States.

(2) Analysis of financial revenue and expenditure and profitability

		Unit: Thousand NT dollars	
	Item	2025	2024
Financial revenue and expenditure	Operating income	4,836,222	5,324,424
	Operating margin	1,050,749	1,011,069
	Operating income	498,710	508,156
	Non-operating income and expenditure	(12,333)	59,194
	Net profit before tax	486,377	567,350
	Net profit after tax	362,201	409,618
Earning power	Return on assets (%)	5.01	5.78
	Return on equity (%)	7.28	9.09
	Ratio of net profit before tax to be paid in capital	48.30	56.34
	Net profit rate (%)	7.49	7.69
	Earnings per share (NT\$)	3.70	4.10

Note: The above amounts are data of the consolidated financial statements of the Company

(3) Research and development

The Company's R&D focuses on product expansion with existing technical advantages and material demand of new industry trends. We take a comprehensive approach encompassing material synthesis, purification, and formulation to ensure a competitive edge:

1. By leveraging our market share in TMAH developer recycling and integrating purification technology and formulation knowledge, we develop IC-grade developer so that recycled products can be returned to IC customers and implement a circular economy.
2. With the rapid development of the IC industry, there is a demand for localization of key materials and the development of relevant special additives for formula improvement.
3. To develop the formula of electronic chemicals in cooperation with the product demand development of LCD, IC packaging, IC manufacturing customers.
4. To cooperate with universities and colleges to develop conductive polymers for lithium batteries, cultivate battery-related talents and strengthen R&D capabilities.
5. With the IC industry advancing towards more advanced processes, there has been a noticeable increase in demand for high-purity chemicals. Utilizing purification technologies to develop high-purity chemicals tailored to customer requirements has become imperative.
6. To research on the absorption and recovery of carbon dioxide, improve the efficiency of energy consumption, we hope to reduce the cost of recovery, and enrich the business of carbon dioxide recovery and purification.
7. The Company is endeavoring to actively engage in the process improvement of existing products PHBA, CHA, DCHA, and TMAH, so as to make the process more energy-saving and efficient for the purpose of reducing costs and creating profits.

For the purchase and update of research and development analytical equipment and analytical methods, the Company continues to purchase and expand more advanced equipment, including: oxygen-free water-free atmosphere gloves box ICP MS/MS (inductively coupled plasma tandem mass spectrometer), LC-MS Q-TOF (liquid chromatography-quadrupole-time-of-flight mass spectrometer), ion chromatography (Ion Chromatography, IC), TGA-DSC (Thermo gravimetric Analyzer, Differential Scanning Calorimetry), etc. in order to meet the ppt level detection limit required by IC customers and serve as tools for application development and analysis of new chemicals.

II. 2026 Business Plan

(1) Business policy

The Company adheres to the business philosophy of “*innovation, integrity and simplicity*”, strives to promote the operation of the Company, utilizes modern advanced technology, gives full play to the wisdom and creativity of all employees, provides various chemicals with high quality and low price to the booming industries, and constantly looks for new supplies to meet new demands and create new business opportunities. This year we continue to implement the following operational strategies:

1. Our Nitto plant for TMAH recycling is actively engaged in production and operation, optimizes production process, stabilizes quality, actively promotes customer use, and especially target T company recycling.
2. Vietnam gas company and material company business development, strive to increase turnover.

3. Continue to expand our customer base in semiconductor industry, develop new chemical applications, and increase market share.
4. The factory continues to improve and expand, making it the most well-equipped semiconductor-grade electronic chemical factory in Taiwan.
5. Continuous improvement in PHBA production processes and cost reduction efforts, coupled with improved coordination between production and sales, aim to increase market share.
6. The Company is endeavoring to integrate the related products of Sanfu Biotech Co., Ltd. and the Sanfu Group and its affiliates in order to build a more professional and rigorous food and biotech related industry.
7. The Company plans to establish a branch plant in Qiaotou, South Taiwan Science Park to meet Company T's chemical needs, strengthen production capacity, and ensure an adequate supply of chemicals.
8. We continue to seek international technical cooperation for working together to improve technical standards.

(2) Production and marketing policies

1. Balancing sales and production: Maintain a certain amount of inventory, and prepare more inventories when price is low.
2. Delivery adopts first in first out (FIFO) principle to keep the freshness of products.
3. Improve product quality and stability, do a good job in quality control, and achieve the goal of zero customer complaints.
4. Constantly improve the process and reduce the cost to improve the market competitiveness.
5. Actively render services to customers and visit customers in order to win customers' long-term trust.

(3) Outlook

The Company's strategy is still to draw up individual business strategy roadmaps according to different business units, combine the wisdom and creativity of all employees, and use effective enterprise resources management system at the same time to work together to increase the overall competitiveness of the Company, so as to make the Company become a sustainable enterprise for operating business in the long run.

Developer (TMAH) Recycling Division: Validation at Company T's 8-inch fab began in Q3 of 2025. PRS has completed the validation at the end of last year, and the first data review for STR, including yield rates, is expected to be completed in Q1 of 2026. This paves the way for the start of burn-in testing in Q2 of 2026, with the goal of completing testing at the 8-inch fab by the end of next year.

Regarding the validation at Company U, testing using pump carts for 22nm and 28nm processes at the 12-inch fab is ongoing. We expect to complete the validation, including application yield (Level 1) for customer products, by the end of the year. At the 8-inch fab, the feed-in validation using the "Coke bottle" method for the 8S and 8C processes at the 28nm end is still ongoing, and testing for the 8A/B processes will be gradually added.

We remain committed to our efforts in the IC sector of the TMAH business. Through our efforts throughout the year, we hope that starting the year after next, Company U will enter its harvest phase, and Company T will successfully begin validation at its 12-inch fab.

Regarding the SOE of the recycling plant, driven by Company T's simultaneous expansion across the north, central, and southern regions, as well as new plant demand from the DRAM industry, which is expanding due to the recovery of the AI market, profits are expected to increase significantly in the second half of the year compared to the same period last year.

Specialty Chemicals Division: In 2026, the Company will continue to focus on the development of next-generation chemicals, driven primarily by the adoption of high-end products by customers and growing demand resulting from ongoing improvements in process specifications. As panel-level packaging technologies evolve, related processes are gradually giving rise to diverse and differentiated new demands for chemicals, presenting new opportunities for expanding the applications of the Company's products.

These developments have been driven by the long-standing and close technical collaboration between the Company's in-house R&D team and its clients. Through the design of customized chemicals and joint participation in the development of panel-level packaging processes—with the most tangible results coming from collaboration on glass substrate technology—we have gradually established a mutually beneficial partnership model. In addition, the Company continues to strategically position itself in the field of silicon photonics applications, laying a solid foundation for future operational growth and technological advancement.

As mentioned earlier, driven by the significant growth trend in the AI industry, capacity for 5nm and below front-end foundry services and HBM-related memory remains tight. Analysts project that Taiwan's semiconductor industry will continue to see double-digit growth in 2026, with an estimated 10% increase to NT\$7.1 trillion. In 2026, Sanfu's focus in the semiconductor chemicals market will be divided into three key areas: First is the ongoing development plan for "key customers." This year, the Company will introduce new formulations and product lines, aligning with customers' new production capacities and emerging technologies (e.g., WMCM, CoPoS, SoIC). Sanfu will progressively allocate resources to hardware, software, and plant expansions, prioritizing applications for advanced packaging processes related to AI; Second is the "developer solution product". In response to Nitto's new plant coming online, an estimated 3–4 key IC clients are expected to initiate certification processes. It is anticipated that domestic and international 8-inch and 12-inch clients will begin using these products in the first half of the year. In 2026, this will be complemented by EBR's recycling solution portfolio and Sanfu's proprietary dispensing product development, forming Sanfu's core product portfolio; Third, business opportunities arising from "domestic clients establishing overseas facilities," including 12-inch fab projects in Singapore, India, and the U.S. Shipments to Singapore began in early 2026, with additional product lines expected to be added by mid-year. Additionally, discussions regarding chemical shipments to India and the U.S. have already commenced.

Domestic Sales Unit of Basic Chemicals Division: Continuing the market expansion initiated in 2025 through the development of new products such as stevia glycosides, lactic acid series, etc., we will also continue to introduce new products and develop new suppliers. These include natural caramel colorants, sustained-release chlorine tablets, amino acid series, etc. Following market trends, we will develop forward-looking new products to meet market demand. Actively seeking competitive domestic small and medium-sized enterprises for mergers and acquisitions or strategic alliances, aiming to increase the market share of main products and supplement product lines. Developing new applications for existing products to break away from the intense price competition in the saturated market and maintain core

competitiveness in the field.

In accordance with government regulations on food safety management, a new food additives plant has been rebuilt in the Tainan County Environment Science Park, and it is dedicated solely to food production by San Fu Biotech Co., Ltd. leading to greater confidence in our services among customers. We have strengthened our professional product quality control analysis and testing capabilities and enhanced product quality control within the Company, meeting customer needs and improving our corporate image under a comprehensive quality assurance system.

Export Unit of Basic Chemicals Division: The Company will stabilize the order of Taiwan pHBA key customers, through RD's research and development results, under the guidance and assistance of the consultant team, and constantly strive to improve the production equipment, hoping to optimize the process to reduce the unit cost, and to strengthen the existing operating profit and product competitiveness, that is, to increase the capacity of the equipment with the minimum investment, to improve and stabilize the quality, to enhance the efficiency of by-product recycling, to reduce the unit consumption of raw materials, and to create more profits for the Company. We also reduce the consumption of raw materials to create greater profits for the Company.

Attachment 2

San Fu Chemical Co., Ltd.

Audit Committee Report

The Board of Directors presented the Company's 2025 annual business report and financial statements (including consolidated financial statements), of which the financial statements (including consolidated financial statements) have been audited by Vivian Yeh and Leon Huang, the certified accountants of Deloitte & Touche Taiwan and issued an audit report.

The above-mentioned business report and financial statements were hereby submitted to and approved by the Company's Audit Committee in conformity with the relevant provisions of the Company Act and in accordance with the provisions of Article 14, Paragraph 4 of the Securities and Exchange Act and Article 219 of the Company Act.

To: 2026 General Shareholders' Meeting of San Fu Chemical Co., Ltd.

Audit Committee Convener: Wu Dong-Ming



March 13, 2026

Attachment 3

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
San Fu Chemical Co., Ltd.

Opinion

We have audited the accompanying consolidated financial statements of San Fu Chemical Co., Ltd. and its subsidiaries (collectively referred to as the “**Company**”), which comprise the consolidated balance sheets as of the years ended December 31, 2025 and 2024, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to the consolidated financial statements, including a summary of significant accounting policies (collectively referred to as the “consolidated financial statements”).

In our opinion and in accordance with the report of other auditors (please refer to the explanation under the paragraph “Other Matter), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of the years ended December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards generally accepted in the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on the audit results of our accountants and the audit reports of other accountants, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion based on our audits and the report of other auditors.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's consolidated financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter of the Company's consolidated financial statements for the year ended December 31, 2025 is stated as follows:

Occurrence of Sales Revenue

The operating income of San Fu Chemical Co., Ltd. and its subsidiaries mainly comes from the sales of fine chemicals, basic chemicals and others. For accounting policies and information related to revenue, please refer to Notes 4 and 21 of the consolidated financial statements. Fine chemical products include the sale of fine chemicals. Domestic sales of fine chemicals are partly transported and delivered by tanker trucks. The actual delivery quantity on the scale or shipping order must be checked to confirm the occurrence of sales transactions. In addition, the revenue of domestic sales of fine chemicals of NT\$2,909,497,000 is the main business item of the Company. Moreover, transactions are frequent, and its revenue in 2025 accounted for approximately 60% of the net operating income in the consolidated financial statements. Therefore, for the domestic sales of fine chemicals, the occurrence of related sales transactions is listed as a key audit matter for this year.

The main audit procedures performed by our accountants on the above matters are as follows:

1. We understood the relevant internal control systems for sales transactions and test their design and implementation effectiveness.
2. We sampled the sales details of domestic fine chemicals and check them with the scale list or shipping documents to confirm the occurrence of sales transactions, and randomly check the collection records of samples that have expired before the reporting deadline to further prove the occurrence of the income.

Other Matter

Among the subsidiaries included in the consolidated financial statements of San Fu Chemical Co., Ltd. and its subsidiaries, the accompanying financial statements of Bio Phoenix Co., Ltd. (BPC), Vina San Fu Industrial Gas Company Limited and Vina San Fu Material Company Limited for the year ended December 31, 2025 and the accompanying financial statements of San Fu Biotech Co. Ltd., Vina San Fu Industrial Gas Company Limited and Vina San Fu Material Company Limited for the year ended December 31, 2024 have not been audited by the accountants of the Deloitte & Touche, Taipei, Taiwan, but by other accountants. Therefore, in the opinions expressed by the accountants on the above-mentioned consolidated financial statements, the amounts listed in the aforementioned company's financial statements are based on the audit reports of other accountants. The total assets of these subsidiaries on December 31, 2025 and December 31, 2024 were respectively NT\$ 1,069,335,000 and NT\$1,552,539,000, which accounted for 13% and 21% respectively of the total consolidated assets. The net operating income from January 1 to December 31, 2025 and from January 1 to December 31, 2024 was respectively NT\$198,479,000 and NT\$617,213,000, which accounted for 4% and 12% respectively of the consolidated operating income.

We have also audited the parent Company only financial statements of the San Fu Chemical Co., Ltd. as of and for the years ended December 31, 2025 and 2024 on which we have issued an unmodified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including supervisors, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards generally accepted in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the auditing standards generally accepted in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Yeh, Shu-Juan and Huang, Guo-Ning.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 12, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

This is the translation of the financial statements. CPAs do not audit or review on this translation.

San Fu Chemical Co., Ltd. and Subsidiaries

CONSOLIDATED BALANCE SHEETS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (In thousands of New Taiwan Dollars)

Code		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%
ASSETS					
CURRENT ASSETS					
1100	Cash (Notes 4 and 6)	\$ 930,682	11	\$ 520,648	7
1136	Financial assets at amortized cost - current (Notes 4 and 8)	315,059	4	293,634	4
1140	Contract asset - current (Notes 4 and 21)	16,255	-	8,167	-
1150	Notes receivable, net (Notes 4 and 9)	34,360	-	36,716	-
1170	Accounts receivable, net (Notes 4 and 9)	1,059,576	13	1,124,860	15
1180	Receivables from related parties (Notes 4 and 29)	9,836	-	6,517	-
130X	Inventories (Notes 4 and 10)	693,971	8	703,758	10
1410	Prepayments (Note 21)	84,600	1	131,922	2
1220	Current tax assets	77	-	543	-
1470	Other current assets	71,496	1	90,414	1
11XX	Total current assets	<u>3,215,912</u>	<u>38</u>	<u>2,917,179</u>	<u>39</u>
NONCURRENT ASSETS					
1517	Financial asset at fair value through other comprehensive income – noncurrent (Notes 4 and 7)	1,127,684	13	154,712	2
1550	Investments accounted for using equity method (Notes 4 and 12)	453,208	6	472,442	6
1600	Property, plant and equipment (Notes 4 and 13)	3,269,216	39	3,391,968	46
1755	Right-of-use assets (Notes 4 and 14)	244,376	3	260,584	4
1780	Intangible assets (Notes 4 and 15)	106,420	1	121,004	2
1840	Deferred income tax assets (Notes 4 and 23)	25,932	-	21,181	-
1915	Prepayments for equipment	6,178	-	41,336	1
1920	Refundable deposits	6,519	-	13,226	-
1990	Net defined benefit liability, noncurrent (Notes 4 and 19)	14,063	-	8,107	-
15XX	Total noncurrent assets	<u>5,253,596</u>	<u>62</u>	<u>4,484,560</u>	<u>61</u>
1XXX	TOTAL	<u>\$ 8,469,508</u>	<u>100</u>	<u>\$ 7,401,739</u>	<u>100</u>
LIABILITIES AND EQUITY					
CURRENT LIABILITIES					
2100	Short-term loans (Note 16)	\$ 2,000,000	24	\$ 1,820,000	25
2130	Contract liabilities – current (Notes 4 and 21)	39,874	-	32,793	-
2170	Notes and accounts payable (Note 17)	265,091	3	259,461	4
2180	Accounts payable - related parties (Note 29)	10,272	-	10,584	-
2200	Other payables (Note 18)	290,525	3	329,637	4
2230	Current tax liabilities (Notes 4 and 23)	47,263	1	71,667	1
2280	Lease liabilities-current (Notes 4 and 14)	20,400	-	21,644	-
2320	Long-term liabilities - current portion (Note 16)	-	-	75,000	1
2399	Other current liabilities	1,043	-	723	-
21XX	Total current liabilities	<u>2,674,468</u>	<u>31</u>	<u>2,621,509</u>	<u>35</u>

(Continued)

San Chi Chemical Co., Ltd. and Subsidiaries

CONSOLIDATED BALANCE SHEETS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In thousands of New Taiwan Dollars)

Code		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%
ASSETS					
NONCURRENT LIABILITIES					
2570	Deferred income tax liabilities (Notes 4 and 23)	210,947	3	8,605	-
2580	Lease liabilities-noncurrent (Notes 4 and 14)	169,184	2	176,537	2
2670	Other noncurrent liabilities	<u>30,087</u>	-	<u>31,341</u>	<u>1</u>
25XX	Total noncurrent liabilities	<u>410,218</u>	<u>5</u>	<u>216,483</u>	<u>3</u>
2XXX	Total liabilities	<u>3,084,686</u>	<u>36</u>	<u>2,837,992</u>	<u>38</u>
EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT (Notes 4 and 20)					
Capital Stock					
3110	Ordinary shares	<u>1,007,060</u>	<u>12</u>	<u>1,007,060</u>	<u>14</u>
3200	Capital surplus	<u>269,376</u>	<u>3</u>	<u>418,027</u>	<u>6</u>
Retained earnings					
3310	Legal capital reserve	530,892	6	489,056	6
3320	Special capital reserve	37,488	1	71,982	1
3350	Unappropriated earnings	<u>2,734,296</u>	<u>32</u>	<u>2,570,124</u>	<u>35</u>
3300	Total retained earnings	<u>3,302,676</u>	<u>39</u>	<u>3,131,162</u>	<u>42</u>
Others					
3410	Exchange differences on translating foreign operations	(51,336)	(1)	(1,377)	-
3420	Unrealized evaluation gains and losses of the equity instrument investment benefit measured at fair value through other comprehensive income	<u>736,422</u>	<u>9</u>	<u>(36,112)</u>	<u>(1)</u>
3400	Total other equity	<u>685,086</u>	<u>8</u>	<u>(37,489)</u>	<u>(1)</u>
31XX	Equity attributable to shareholders of the parent	<u>5,264,198</u>	<u>62</u>	<u>4,518,760</u>	<u>61</u>
36XX	NON-CONTROLLING INTERESTS (Note 20)	<u>120,624</u>	<u>2</u>	<u>44,987</u>	<u>1</u>
3XXX	Total equity	<u>5,384,822</u>	<u>64</u>	<u>4,563,747</u>	<u>62</u>
TOTAL		<u>\$ 8,469,508</u>	<u>100</u>	<u>\$ 7,401,739</u>	<u>100</u>

(Concluded)

The accompanying notes are an integral part of the consolidated financial statements.

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang

San Fu Chemical Co., Ltd. and Subsidiaries

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

Code		2025		2024	
		Amount	%	Amount	%
4000	NET REVENUE (Notes 4, 21 and 29)	\$ 4,836,222	100	\$ 5,324,424	100
5000	COST OF REVENUE (Notes 10, 22 and 29)	<u>3,785,473</u>	<u>78</u>	<u>4,313,355</u>	<u>81</u>
5900	GROSS PROFIT	<u>1,050,749</u>	<u>22</u>	<u>1,011,069</u>	<u>19</u>
	OPERATING EXPENSES (Notes 22 and 29)				
6100	Marketing	242,450	5	247,784	5
6200	General and administrative	164,799	4	167,936	3
6300	Research & development	143,908	3	86,710	2
6450	Expected credit impairment losses	<u>882</u>	<u>-</u>	<u>483</u>	<u>-</u>
6000	Total operating expenses	<u>552,039</u>	<u>12</u>	<u>502,913</u>	<u>10</u>
6900	INCOME FROM OPERATIONS	<u>498,710</u>	<u>10</u>	<u>508,156</u>	<u>9</u>
	NON-OPERATING INCOME AND EXPENSES				
7010	Other income (Notes 22 and 29)	42,222	1	29,937	1
7020	Other gains and losses (Note 22)	(40,764)	(1)	34,920	1
7050	Finance cost (Note 22)	(43,859)	(1)	(37,232)	(1)
7060	Share of profit or loss of associates and joint ventures Recognized by Equity Method (Notes 4 and 12)	15,566	1	20,687	-
7100	Interest income	<u>14,502</u>	<u>-</u>	<u>10,882</u>	<u>-</u>
7000	Total non-operating income and expenses	(<u>12,333</u>)	<u>-</u>	<u>59,194</u>	<u>1</u>
7900	INCOME BEFORE INCOME TAX	486,377	10	567,350	10
7950	INCOME TAX EXPENSE (Notes 4 and 23)	(<u>124,176</u>)	(<u>3</u>)	(<u>157,732</u>)	(<u>3</u>)
8200	NET INCOME	<u>362,201</u>	<u>7</u>	<u>409,618</u>	<u>7</u>

(Continued)

San-Pa Chemical Co., Ltd. and Subsidiaries

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

Code	2025		2024		
	Amount	%	Amount	%	
OTHER COMPREHENSIVE INCOME (LOSS)					
8310	Items that will not be reclassified subsequently to profit or loss:				
8311		760	-	\$ 7,235	-
8316					
8349					
8360	Items that may be reclassified subsequently to profit and loss:				
8361					
8370					
8300					
8500					
NET INCOME ATTRIBUTABLE TO:					
8610					
8620					
8600					
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:					
8710					
8720					
8700					
EARNINGS PER SHARE (Note 24)					
From continuing business units					
9750					
9850					

(Concluded)

The accompanying notes are an integral part of the consolidated financial statements.

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang



Sun Pharmaceutical Co., Ltd. and Subsidiaries

**CONDENSED STATEMENTS OF CHANGES IN EQUITY
FOR PERIODS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)**

	Capital Stock		Equity attributable to the Shareholders of the parent					Others			Sub-Total	Non-controlling interests	Total Equity
	Shares (In Thousands)	Amount	Capital Surplus	Legal Capital Reserve	Retained Earnings		Exchange Differences on Translating Foreign Operations (\$)	Unrealized Gain (Loss) on Financial Assets at FVTOCI (\$)	Unappropriated Earnings				
					Special Capital Reserve	Unappropriated Earnings							
A1	100,706	\$ 1,007,060	\$ 564,657	\$ 444,716	\$ 44,926	\$ 2,424,570	(\$ 45,546)	(\$ 26,436)		\$ 4,413,947	\$ 31,850	\$ 4,445,797	
B1	-	-	-	44,340	-	(44,340)	-	-	-	-	-	-	
B3	-	-	-	-	27,056	(27,056)	-	-	-	-	-	-	
B5	-	-	(151,059)	-	-	(201,412)	-	-	-	(352,471)	-	(352,471)	
M7	-	-	-	81	-	-	-	-	81	16,592	16,592	16,673	
O1	-	-	2,448	-	-	-	-	-	2,448	285	285	2,733	
C3	-	-	1,900	-	-	-	-	-	1,900	1,900	-	1,900	
D1	-	-	-	-	-	412,574	-	-	412,574	(2,956)	(2,956)	409,618	
D3	-	-	-	-	-	-	-	-	-	-	-	-	
D5	-	-	-	-	-	5,788	44,169	(9,676)	40,281	(784)	(784)	39,497	
Z1	100,706	1,007,060	418,027	489,056	71,982	2,570,124	(1,377)	(36,112)	452,855	(3,740)	(3,740)	449,115	
M5	-	-	508	-	-	-	-	-	508	44,987	44,987	45,63,747	
B1	-	-	-	41,836	-	(41,836)	-	-	-	-	-	-	
B5	-	-	(151,059)	-	-	(201,412)	-	-	(352,471)	-	-	(352,471)	
B17	-	-	-	-	(34,494)	34,494	-	-	-	-	-	-	
C3	-	-	1,900	-	-	-	-	-	1,900	-	-	1,900	
O1	-	-	-	-	-	-	-	-	-	91,837	91,837	91,837	
D1	-	-	-	-	-	372,318	-	-	372,318	(10,117)	(10,117)	362,201	
D3	-	-	-	-	-	608	(49,959)	772,534	723,183	1,138	1,138	722,045	
D5	-	-	-	-	-	372,926	(49,959)	772,534	1,095,501	(11,255)	(11,255)	1,084,246	
Z1	100,706	\$ 1,007,060	\$ 269,376	\$ 530,892	\$ 37,488	\$ 2,734,296	(\$ 51,336)	\$ 736,422	\$ 5,264,198	\$ 120,624	\$ 120,624	\$ 5,384,822	

The accompanying notes are an integral part of the consolidated financial statements.

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang


San Fu Chemical Co., Ltd. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

C o d e	<u>2025</u>	<u>2024</u>
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>		
A10000	\$ 486,377	\$ 567,350
A20010	Adjustments for:	
A20100	426,513	425,693
A20200	14,584	14,965
A20300	882	483
A20900	43,859	37,232
A21200	(14,502)	(10,882)
A21300	(1,869)	(1,534)
A21900	-	2,733
A22300	(15,566)	(20,687)
A22500	524	6
A22600	583	145
A23700	-	3,489
A23800	(5,136)	10,576
A24100	7,039	(30,757)
A29900	-	(254)
A30000	Change in operating assets and liabilities	
A31125	(8,088)	2,180
A31130	2,356	1,099
A31150	63,952	178,552
A31160	(13,863)	20,794
A31200	11,959	(35,179)
A31230	46,110	449,310
A31240	24,463	(6,039)
A32125	7,081	(449,138)
A32150	6,870	(174,226)
A32160	30,684	(982)
A32180	1,701	(85,187)
A32230	382	(4,919)
A32240	(5,196)	(8,498)
A32990	(1,254)	(29,529)
A33000	1,110,445	856,796
A33100	14,502	10,882
A33200	1,869	1,534
A33300	(47,191)	(34,742)
A33500	(148,794)	(216,164)
AAA	<u>930,831</u>	<u>618,306</u>

(Continued)

SAI CHEMICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In thousands of New Taiwan Dollars)

C o d e		2025	2024 .
CASH FLOWS FROM INVESTING ACTIVITIES			
B00040	Purchase of financial assets at amortized cost	(\$ 27,721)	(\$ 93,716)
B02700	Purchase of property, plant and equipment	(287,288)	(442,316)
B02800	Gain on Disposal of property, plant and equipment	4,743	-
B03700	Increase in refundable deposits	(506)	-
B03800	Decrease in refundable deposits	-	6,729
B04500	Purchase of intangible assets	(30,000)	(60,000)
B07100	Increase in prepayments for equipment	(14,852)	(34,512)
B07600	Dividend received	<u>22,928</u>	<u>46,310</u>
BBBB	Net cash used in investing activities	(<u>332,696</u>)	(<u>577,505</u>)
CASH FLOWS FROM FINANCING ACTIVITIES			
C00100	Increase in short-term loans	180,000	600,285
C01700	Repayment of Long-term bank loans	(75,000)	(250,000)
C04020	Repayment of the principal portion of lease liabilities	(24,798)	(30,614)
C04500	Payment – Owners’ Dividend	(352,471)	(352,471)
C05400	Equity of a subsidiary acquired	(4,437)	-
C09900	Donations from Shareholders	1,900	1,900
C05800	Change in non-controlling interests	<u>91,837</u>	<u>16,673</u>
CCCC	Net cash used in financing activities	(<u>182,969</u>)	(<u>14,227</u>)
DDDD	EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES	(<u>5,132</u>)	<u>4,852</u>
EEEE	NET INCREASE IN CASH	410,034	31,426
E00100	CASH , BEGINNING OF YEAR	<u>520,648</u>	<u>489,222</u>
E00200	CASH, END OF YEAR	<u>\$ 930,682</u>	<u>\$ 520,648</u>

(Concluded)

The accompanying notes are an integral part of the consolidated financial statements

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
San Fu Chemical Co., Ltd.

Opinion

We have audited the accompanying parent company only financial statements of San Fu Chemical Co., Ltd. (the “**Company**”), which comprise the parent company only balance sheets as of December 31, 2025 and 2024, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to the parent company only financial statements, including a summary of significant accounting policies.

In our opinion and in accordance with the report of other auditors (please refer to the explanation under the paragraph “Other Matter), the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2025 and 2024, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards generally accepted in the Republic of China. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on the audit results of our accountants and the audit reports of other accountants, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion based on our audits and the report of other auditors.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter of the Company’s parent company only financial statements for the year ended December 31, 2025 is stated as follows:

Occurrence of Sales Revenue

The operating income of San Fu Chemical Co., Ltd. mainly comes from the sales of fine chemicals, basic chemicals and others. For accounting policies and information related to revenue, please refer to Notes 4 and 19 of the parent company only financial statements. Fine chemical products include the sale of fine chemicals. Domestic sales of fine chemicals are partly transported and delivered by tanker trucks. The actual delivery quantity on the scale or shipping order must be checked to confirm the occurrence of sales transactions. In addition, the revenue of domestic sales of fine chemicals of NT\$2,909,497,000 is the main business item of the Company. Moreover, transactions are frequent, and its revenue in 2025 accounted for approximately 69% of the net operating income in the parent company only financial statements. Therefore, for the domestic sales of fine chemicals, the occurrence of related sales transactions is listed as a key audit matter for this year.

The main audit procedures performed by our accountants on the above matters are as follows:

1. We understood the relevant internal control systems for sales transactions and test their design and implementation effectiveness.
2. We sampled the sales details of domestic fine chemicals and check them with the scale list or shipping documents to confirm the occurrence of sales transactions, and randomly check the collection records of samples that have expired before the reporting deadline to further prove the occurrence of the income

Other Matter

Among the investments accounted for under the equity method of the subsidiaries included in the parent company only financial statements of San Fu Chemical Co., Ltd., the accompanying financial statements of Bio Phoenix Co., Ltd. (BPC), Vina San Fu Industrial Gas Company Limited and Vina San Fu Material Company Limited for the year ended December 31, 2025 and the accompanying financial statements of San Fu Biotech Co. Ltd., Vina San Fu Industrial Gas Company Limited and Vina San Fu Material Company Limited for the year ended December 31, 2024 have not been audited by the accountants of the Deloitte & Touche, Taipei, Taiwan, but by other accountants.

Therefore, the opinion expressed by this accountant regarding the equity method investment balance of the aforementioned investee companies in the parent only financial statements is based on the audit report of other accountants. As of and for the years ended December 31, 2025 and 2024, the equity method investment balances of the aforementioned investee companies were NT\$529,972,000 and NT\$784,831,000, respectively, representing 7% and 12% of the total assets of San Fu Chemical Co., Ltd.; the equity method investment balances of gains and losses of the subsidiaries, associates and joint ventures of the aforementioned investee companies as of January 1 to December 31, 2025 and 2024, were (NT\$169,446,000) and (NT\$96,617,000), respectively, representing (15%) and (21%) of the total parent only profit and loss of the Company (San Fu Chemical Co., Ltd.) for each year.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for maintaining necessary internal controls as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including supervisors, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards generally accepted in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the auditing standards generally accepted in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain

audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Yeh, Shu-Juan and Huang, Guo-Ning.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 12, 2026

Notice to Readers

The accompanying parent company only financial statements are intended only to present the parent company only financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally applied in the Republic of China.

This is the translation of the financial statements. CPAs do not audit or review on this translation.

San Tai Chemical Co., Ltd.

PARENT COMPANY ONLY BALANCE SHEETS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

Code		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%
ASSETS					
CURRENT ASSETS					
1100	Cash (Notes 4 and 6)	\$ 603,446	8	\$ 282,804	4
1136	Financial assets at amortized cost - current (Note 8)	128,973	2	127,005	2
1140	Contract asset - current (Notes 4 and 19)	16,255	-	8,167	-
1150	Notes receivable, net (Notes 4 and 9)	8,557	-	8,252	-
1170	Accounts receivable, net (Notes 4 and 9)	949,678	13	1,022,879	15
1180	Receivables from related parties (Notes 4 and 26)	649,791	9	640,586	10
130X	Inventories (Notes 4 and 10)	556,985	7	578,241	9
1410	Prepayments (Note 19)	47,845	1	94,742	2
1470	Other current assets	<u>20,673</u>	-	<u>23,168</u>	-
11XX	Total current assets	<u>2,982,203</u>	<u>40</u>	<u>2,785,844</u>	<u>42</u>
NONCURRENT ASSETS					
1517	Financial asset at fair value through other comprehensive income – noncurrent (Notes 4 and 7)	32,995	1	35,853	1
1550	Investments accounted for using equity method (Notes 4 and 11)	3,130,845	43	2,575,863	38
1600	Property, plant and equipment (Notes 4 and 12)	1,132,118	15	1,155,515	17
1755	Right-of-use assets (Notes 4 and 13)	51,528	1	55,458	1
1840	Deferred income tax assets (Notes 4 and 21)	25,811	-	21,181	-
1915	Prepayments for equipment	6,178	-	38,558	1
1920	Refundable deposits	5,977	-	12,779	-
1990	Net defined benefit liability, noncurrent (Notes 4 and 17)	<u>14,063</u>	-	<u>8,107</u>	-
15XX	Total noncurrent assets	<u>4,399,515</u>	<u>60</u>	<u>3,903,314</u>	<u>58</u>
1XXX	TOTAL	<u>\$ 7,381,718</u>	<u>100</u>	<u>\$ 6,689,158</u>	<u>100</u>

LIABILITIES AND EQUITY

CURRENT LIABILITIES

2100	Short-term loans (Note 14)	\$ 1,500,000	20	\$ 1,460,000	22
2130	Contract liabilities – current (Notes 4 and 19)	39,874	1	32,793	1
2170	Notes and accounts payable (Note 15)	216,974	3	227,891	4
2180	Accounts payable - related parties (Note 26)	36,365	-	23,667	-
2200	Other payables (Note 16)	225,103	3	222,668	3
2230	Current tax liabilities (Notes 4 and 21)	42,165	1	71,667	1
2280	Lease liabilities-current (Notes 4 and 13)	14,387	-	15,229	-
2320	Long-term liabilities - current portion (Note 14)	-	-	75,000	1
2399	Other current liabilities	<u>415</u>	-	<u>533</u>	-
21XX	Total current liabilities	<u>2,075,283</u>	<u>28</u>	<u>2,129,448</u>	<u>32</u>

(Continued)

San-E Chemical Co., Ltd.

PARENT COMPANY ONLY BALANCE SHEETS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

Code		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%
ASSETS					
NONCURRENT LIABILITIES					
2570	Deferred income tax liabilities	4,404	-	-	-
2580	Lease liabilities-noncurrent (Notes 4 and 13)	37,781	1	40,577	-
2670	Other noncurrent liabilities	<u>52</u>	-	<u>373</u>	-
25XX	Total noncurrent liabilities	<u>42,237</u>	<u>1</u>	<u>40,950</u>	-
2XXX	Total liabilities	<u>2,117,520</u>	<u>29</u>	<u>2,170,398</u>	<u>32</u>
EQUITY (Notes 4 and 18)					
Capital Stock					
3110	Ordinary shares	<u>1,007,060</u>	<u>13</u>	<u>1,007,060</u>	<u>15</u>
3200	Capital surplus	<u>269,376</u>	<u>4</u>	<u>418,027</u>	<u>6</u>
Retained earnings					
3310	Legal capital reserve	530,892	7	489,056	7
3320	Special capital reserve	37,488	1	71,982	1
3350	Unappropriated earnings	<u>2,734,296</u>	<u>37</u>	<u>2,570,124</u>	<u>39</u>
3300	Total retained earnings	<u>3,302,676</u>	<u>45</u>	<u>3,131,162</u>	<u>47</u>
Others					
3410	Exchange differences on translating foreign operations	(51,336)	(1)	(1,377)	-
3420	Unrealized evaluation gains and losses of the equity instrument investment benefit measured at fair value through other comprehensive income	<u>736,422</u>	<u>10</u>	<u>(36,112)</u>	-
3400	Total other equity	<u>685,086</u>	<u>9</u>	<u>(37,489)</u>	-
3XXX	Total equity	<u>5,264,198</u>	<u>71</u>	<u>4,518,760</u>	<u>68</u>
TOTAL		<u>\$ 7,381,718</u>	<u>100</u>	<u>\$ 6,689,158</u>	<u>100</u>

(Concluded)

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang

Sanmin Chemical Co., Ltd.



PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

Code		2025		2024	
		Amount	%	Amount	%
4000	NET REVENUE (Notes 4, 19 and 26)	\$ 4,202,380	100	\$ 4,735,841	100
5000	COST OF REVENUE (Notes 10, 20 and 26)	<u>3,176,593</u>	<u>76</u>	<u>3,676,889</u>	<u>77</u>
5900	GROSS PROFIT	<u>1,025,787</u>	<u>24</u>	<u>1,058,952</u>	<u>23</u>
	OPERATING EXPENSES (Notes 20 and 26)				
6100	Marketing	177,694	4	191,736	4
6200	General and administrative	124,958	3	120,976	3
6300	Research & development	55,051	1	55,535	1
6450	Expected credit impairment losses	<u>220</u>	<u>-</u>	<u>-</u>	<u>-</u>
6000	Total operating expenses	<u>357,923</u>	<u>8</u>	<u>368,247</u>	<u>8</u>
6900	INCOME FROM OPERATIONS	<u>667,864</u>	<u>16</u>	<u>690,705</u>	<u>15</u>
	NON-OPERATING INCOME AND EXPENSES				
7010	Other income (Notes 20 and 26)	37,888	1	25,821	1
7020	Other gains and losses (Note 20)	(29,895)	(1)	53,212	1
7050	Finance cost (Note 20)	(31,955)	(1)	(28,487)	(1)
7070	Share of FVTOCI of subsidiaries, associates and joint ventures recognized by equity method (Notes 4 and 11)	(174,108)	(4)	(190,734)	(4)
7100	Interest income	<u>19,200</u>	<u>1</u>	<u>14,841</u>	<u>-</u>
7000	Total non-operating income and expenses	<u>(178,870)</u>	<u>(4)</u>	<u>(125,347)</u>	<u>(3)</u>
7900	INCOME BEFORE INCOME TAX	488,994	12	565,358	12
7950	INCOME TAX EXPENSE (Notes 4 and 21)	<u>(116,676)</u>	<u>(3)</u>	<u>(152,784)</u>	<u>(3)</u>
8200	NET INCOMNE	<u>372,318</u>	<u>9</u>	<u>412,574</u>	<u>9</u>

(Continued)

Sarri Chemical Co., Ltd.

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

<u>Code</u>	<u>2025</u>		<u>2024</u>	
	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
OTHER COMPREHENSIVE INCOME (LOSS)				
8310 Items that will not be reclassified subsequently to profit or loss:				
8311 Remeasurement of defined benefit obligation (Note 17)	760	-	7,235	-
8316 Unrealized gain or loss on investments in equity instruments at FVTOCI (Note 7)	(2,858)	-	(9,676)	-
8349 Income tax related to items that will not be reclassified	(152)	-	(1,447)	-
	(2,250)	-	(3,888)	-
8360 Items that may be reclassified subsequently to profit and loss:				
8380 Share of FVTOCI of subsidiaries, associates and joint ventures recognized by equity method	725,433	17	44,169	1
	725,433	17	44,169	1
8300 Other comprehensive income (loss), net of income tax	723,183	17	40,281	1
8500 TOTAL COMPREHENSIVE INCOME	<u>\$ 1,095,501</u>	<u>26</u>	<u>\$ 452,855</u>	<u>10</u>
EARNINGS PER SHARE (Note 22)				
9710 Basic earnings per share	<u>\$ 3.70</u>		<u>\$ 4.10</u>	
9810 Diluted earnings per share	<u>\$ 3.69</u>		<u>\$ 4.09</u>	

(Concluded)

The accompanying notes are an integral part of the parent company only financial statements.

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang



Singway Chemical Co., Ltd.

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
PERIODS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	Capital Stock		Capital Surplus	Legal Capital Reserve	Retained Earnings		Unappropriated Earnings	Exchange Differences on Translating Foreign Operations	Others	Unrealized Gain (Loss) on Financial Assets at FVTOCI	Total Equity
	Shares (In Thousands)	Amount			Special Capital Reserve	Unappropriated Earnings					
A1 BALANCE, JANUARY 1, 2024	100,706	\$ 1,007,060	\$ 564,657	\$ 444,716	\$ 44,926	\$ 2,424,570	(\$ 45,546)	(\$ 26,436)		\$ 4,413,947	
M7 From share of changes in equities of subsidiaries	-	-	081	-	-	-	-	-	-	81	
O1 Employee restricted shares retired	-	-	2,448	-	-	-	-	-	-	2,448	
B1 Distribution of available earnings for 2023	-	-	-	44,340	-	(44,340)	-	-	-	-	
B3 Recognized legal capital reserve	-	-	-	-	27,056	(27,056)	-	-	-	-	
B5 Recognized special capital reserve	-	-	-	-	-	(201,412)	-	-	-	(352,471)	
Cash Dividend to Shareholders	-	-	(151,059)	-	-	-	-	-	-	-	
Other Changes in Equity:											
C3 Donation from Shareholders	-	-	1,900	-	-	-	-	-	-	1,900	
D1 NET INCOME FOR 2024	-	-	-	-	-	412,574	-	-	-	412,574	
D3 Other Comprehensive Income (loss) after Tax for 2024	-	-	-	-	-	5,788	44,169	(9,676)	-	40,281	
D5 Total Comprehensive Income (loss) for 2024	-	-	-	-	-	418,362	44,169	(9,676)	-	452,855	
Z1 BALANCE, DECEMBER 31, 2024	100,706	1,007,060	418,027	489,056	71,982	2,570,124	(1,377)	(36,112)		4,518,760	
M5 Equities acquired from subsidiaries	-	-	508	-	-	-	-	-	-	508	
Distribution of available earnings for 2024											
B1 Recognized legal capital reserve	-	-	-	41,836	-	(41,836)	-	-	-	-	
B3 Reversal of special capital reserve	-	-	-	-	(34,494)	34,494	-	-	-	-	
B5 Cash dividend to shareholders	-	-	(151,059)	-	-	(201,412)	-	-	-	(352,471)	
Other changes in capital surplus											
C3 Donations from Shareholders	-	-	1,900	-	-	-	-	-	-	1,900	
D1 Net Income in 2025	-	-	-	-	-	372,318	-	-	-	372,318	
D3 Other comprehensive income (loss) in 2025	-	-	-	-	-	608	(49,959)	772,534	-	723,183	
D5 Total Comprehensive Income (loss) in 2025	-	-	-	-	-	372,926	(49,959)	772,534	-	1,095,501	
Z1 BALANCE DECEMBER 31, 2025	100,706	\$ 1,007,060	\$ 269,376	\$ 530,892	\$ 37,488	\$ 2,734,296	(\$ 51,336)	\$ 736,422		\$ 5,264,198	

The accompanying notes are an integral part of the parent company only financial statements.

Chairman: Hsin-Hung Wu

Manager: Tien-Pao Su

Chief Accounting Officer: Ling-Feng Chang

San-Ei Chemical Co., Ltd.

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

C o d e		2025	2024
	CASH FLOWS FROM OPERATING ACTIVITIES		
A10000	Income before income tax	\$ 488,994	\$ 565,358
A20010	Adjustments for:		
A20100	Depreciation expense	248,642	278,510
A20300	Expected credit losses	220	-
A20900	Finance costs	31,955	28,487
A21200	Interest income	(19,200)	(14,841)
A21300	Dividend income	(1,869)	(1,534)
A22400	Gain/Loss of subsidiaries, associates and joint ventures using equity method	174,108	190,734
A22600	Transfer fee from property, plant and equipment	274	-
A23800	Allowance to reduce inventory to market ((gain)loss from price recovery of inventory)	(1,676)	526
A24100	Unrealized foreign currency exchange loss (gain)	7,039	(30,757)
A29900	Lease modification benefits	-	(254)
A30000	Change in operating assets and liabilities		
A31125	Contract Assets - Current	(8,088)	2,180
A31130	Notes receivable	(305)	(1,367)
A31150	Accounts receivable	74,798	170,011
A31160	Accounts receivable – related parties	(17,515)	(251,887)
A31200	Inventories	22,932	510
A31230	Prepayments	46,897	443,401
A31240	Other current assets	9,694	(836)
A32125	Contract liability	7,081	(449,138)
A32150	Notes & Accounts payable	(10,621)	(175,487)
A32160	Accounts payable - related parties	12,698	(45,968)
A32180	Other payables	1,166	(22,875)
A32230	Other current liabilities	(118)	(485)
A32240	Net defined benefit liabilities - noncurrent	(5,196)	(8,498)
A32990	Other noncurrent liabilities	(321)	(497)
A33000	Cash generated from operations	1,061,589	675,293
A33100	Interest received	19,200	14,841
A33200	Dividend received	1,869	1,534
A33300	Interest paid	(32,913)	(27,104)
A33500	Income taxes paid	(146,556)	(209,148)
AAA	Net cash generated by operating activities	<u>903,189</u>	<u>455,416</u>

(Continued)

SAN FENG CHEMICAL CO., LTD.

PARIENT COMPANY ONLY STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In thousands of New Taiwan Dollars)

C o d e	2025	2024 .
CASH FLOWS FROM INVESTING ACTIVITIES		
B00040	(\$ 1,968)	(\$ 1,605)
B02700	(167,780)	(166,365)
B03700	(397)	-
B03800	-	3,870
B07100	(4,745)	(10,832)
B07600	<u>1,288</u>	<u>1,095</u>
BBBB	(<u>173,602</u>)	(<u>173,837</u>)
CASH FLOWS FROM FINANCING ACTIVITIES		
C00100	40,000	435,285
C01700	(75,000)	(250,000)
C04020	(18,095)	(19,229)
C04500	(352,471)	(352,471)
C05400	(4,437)	(34,827)
C09900	<u>1,900</u>	<u>1,900</u>
CCCC	(<u>408,103</u>)	(<u>219,342</u>)
DDDD	(<u>842</u>)	<u>1,988</u>
EEEE	320,642	64,225
E00100	<u>282,804</u>	<u>218,579</u>
E00200	<u>\$ 603,446</u>	<u>\$ 282,804</u>

(Concluded)

The accompanying notes are an integral part of the parent company only financial statements

Chairman: Hsin-Hung Wu Manager: Tien-Pao Su Chief Accounting Officer: Ling-Feng Chang

Attachment 4

San Fu Chemical Co., Ltd. Rules for Procedure of Board Meetings (Comparative Table of Certain Current and Amended Articles)

Amended Articles	Current Articles	Explanation
<p>Article 3 The Company's Board of Directors meets once every quarter. The convention of a board meeting shall state the reasons for the meeting and specify the agenda to be given to all directors and supervisors at least seven days prior to the meeting; however, in cases of emergency, a meeting may be convened at any time. The notice of the convention referred to in the preceding paragraph may be served electronically with the consent of the party concerned. <u>Unless there are unforeseen emergencies or justifiable reasons</u>, the matters listed in the subparagraphs of Paragraph 1 of Article 7 of <u>these Rules</u> shall be listed in the notice of meeting and may not be raised as a motion.</p>	<p>Article 3 The Company's Board of Directors shall meet at least once every quarter. The convention of a board meeting shall state the reasons for the meeting and specify the agenda of the meeting, which shall be given to all directors at least seven days prior to the meeting; however, in cases of emergency, a meeting may be convened at any time. The notice of the convention referred to in the preceding paragraph may be served electronically with the consent of the party concerned. The matters specified in the subparagraphs of Paragraph 1 of Article 7 shall be listed in the notice of meeting and may not be raised as a motion.</p>	<p>This article was amended in accordance with regulations.</p>
<p>Article 5 The Company's Board of Directors designates the Finance and Accounting Department as the administrative unit responsible for board affairs. The administrative unit shall prepare the agenda for the board meeting and provide <u>sufficient</u> meeting materials to be sent together with the notice of the meeting. If a director believes that the meeting materials are insufficient, he or she may request the</p>	<p>Article 5 The Company's Board of Directors shall designate the Finance and Accounting Department as the administrative unit responsible for board affairs. The administrative unit shall prepare the agenda for the board meeting and provide <u>enough</u> meeting materials to be sent together with the notice of the meeting. <u>If a director considers the meeting materials are not enough to be insufficient, he or she may request the administrative unit for supplements.</u> If a director believes that the</p>	<p>The text was corrected and paragraphs were moved in accordance with regulations.</p>

<p>administrative unit to provide supplements. If a director believes that the information of a proposal is insufficient, the Board may, upon resolution, postpone the consideration of the proposal.</p>	<p>information of a proposal is he or she may, upon resolution by the board of directors, postpone the consideration of the proposal.</p>	
<p>Article 10</p> <p>Paragraph 1 is omitted.</p> <p><u>If the board meeting is convened by a majority of directors pursuant to Article 203, Paragraph 4, or Article 203-1, Paragraph 3, of the Company Act, one director shall be elected by the directors to serve as chairperson.</u></p> <p>If the Chairman is on leave or otherwise unable to perform his or her duties, the Vice Chairman shall act as his or her proxy. If there is no Vice Chairman, or if the Vice Chairman is also on leave or otherwise unable to perform his or her duties, the Chairman shall designate one Executive Director to act as his or her proxy; if there are no Executive Directors, the Chairman shall designate one Director to act as his or her proxy. If the Chairman fails to designate a proxy, the Executive Directors or Directors shall elect one among themselves to act as his or her proxy.</p>	<p>Article 10</p> <p>Paragraph 1 is omitted.</p> <p>If the Chairman is on leave or otherwise unable to perform his or her duties, the Vice Chairman shall act as his or her proxy. If there is no Vice Chairman, or if the Vice Chairman is also on leave or otherwise unable to perform his or her duties, the Chairman shall designate one Executive Director to act as his or her proxy; if there are no Executive Directors, the Chairman shall designate one Director to act as his or her proxy. If the Chairman fails to designate a proxy, the Executive Directors or Directors shall elect one among themselves to act as his or her proxy.</p> <p><u>If the board meeting is convened by a majority of directors pursuant to Article 203, Paragraph 4, or Article 203-1, Paragraph 3, of the Company Act, one director shall be elected by the directors to serve as chairperson.</u></p>	<p>The order of articles was rearranged in accordance with regulations.</p> <p>Chairperson’s Proxy Mechanism: The method and order for appointing a proxy for the chairperson of the board of directors and committees are specified when the chairperson is unable to perform his or her duties for any reason, thereby ensuring the continuity of proceedings.</p>
<p>Article 11</p> <p><u>When the Company’s Board of Directors convenes, the relevant management departments (or the deliberative units designated by the Board) shall prepare the necessary materials for the directors’ reference at any time.</u></p> <p>When convening a board meeting,</p>	<p>Article 11</p> <p>When convening a board meeting,</p>	<p>This article was amended in accordance with regulations, a new paragraph 1 was added, and the original paragraphs were renumbered.</p>

<p>the Company may, depending on the nature of the agenda, notify personnel from relevant departments or subsidiaries to attend as observers.</p> <p>When necessary, the Company may also invite certified public accountants, attorneys, or other professionals to attend the meeting and provide explanations. However, such individuals shall leave the meeting during discussions and voting.</p>	<p>the Company may, depending on the nature of the agenda, notify personnel from relevant departments or subsidiaries to attend as observers.</p> <p>When necessary, the Company may also invite certified public accountants, attorneys, or other professionals to attend the meeting and provide explanations. However, such individuals shall leave the meeting during discussions and voting.</p>	
<p>Article 12</p> <p><u>The chairperson of the board meeting shall call the meeting to order immediately upon the scheduled time if a majority of the directors are present.</u></p> <p>If, at the scheduled time, less than half of all directors are present, the chairperson may announce a postponement of the meeting to a later time on the same day; such postponements shall be limited to two instances. If the quorum is still not met after two postponements, the chairperson may reconvene the meeting in accordance with the procedures set forth in Article 3, Paragraph 2.</p> <p>The term “all directors” as described in the preceding paragraph and in Article 17, Paragraph 2, Subparagraph 2, shall be calculated based on the number of directors actually in office.</p>	<p>Article 12</p> <p>If, at the scheduled time, less than half of all directors are present, the chairperson may announce a postponement of the meeting to a later time on the same day; such postponements shall be limited to two instances. If the quorum is still not met after two postponements, the chairperson may reconvene the meeting in accordance with the procedures set forth in Article 3, Paragraph 2.</p> <p>The term “all directors” as described in the preceding paragraph and in Article 17, Paragraph 2, Subparagraph 2, shall be calculated based on the number of directors actually in office.</p>	<p>This article was amended in accordance with regulations, and the original paragraphs were renumbered.</p>

<p>Article 14</p> <p>When the Chairperson deems that the discussion of a proposal at a board meeting has reached a stage where it may be put to a vote, the Chairperson may declare the discussion closed and put the item to a vote.</p> <p>When voting on a proposal at <u>the Company’s</u> board meeting, if the chairperson consults <u>all</u> attending directors and finds no objections, the proposal shall be deemed approved. If, upon consultation by the chairperson, any objections are raised, the proposal shall be put to a vote.</p> <p>The method of voting shall be selected by the chairperson from among the following options; however, if any attendee objects, the decision shall be made by a majority vote:</p> <ol style="list-style-type: none"> 1. A show of hands or voting device. 2. A roll call vote. 3. A secret ballot. 4. A voting method selected by the Company. <p>The term “all directors present” as used in the preceding two paragraphs does not include directors who are prohibited from exercising voting rights pursuant to Article 16, Paragraph 1.</p>	<p>Article 14</p> <p>When the Chairperson deems that the discussion of a proposal at a board meeting has reached a stage where it may be put to a vote, the Chairperson may declare the discussion closed and put the item to a vote.</p> <p>When a proposal is put to a vote at a board meeting, if the chairperson asks the directors present and none object, the proposal shall be deemed adopted, and <u>such adoption shall have the same effect as a proposal passed by a vote.</u></p> <p>The method of voting shall be selected by the chairperson from among the following options; however, if any attendee objects, the decision shall be made by a majority vote:</p> <ol style="list-style-type: none"> 1. A show of hands or voting device. 2. A roll call vote. 3. A secret ballot. 4. A voting method selected by the Company. <p>The term “all directors present” as used in the preceding two paragraphs does not include directors who are prohibited from exercising voting rights pursuant to Article 16, Paragraph 1.</p>	<p>This article was amended in accordance with regulations, and the original paragraphs were renumbered.</p>
<p>Article 15</p> <p>Resolutions on proposal at a board meeting shall, unless otherwise provided by the <u>Securities and Exchange Act</u> or the Company Act, be adopted with the attendance of a majority of the directors and the consent of a majority of the directors present.</p> <p>Paragraphs 2 to 5 are Omitted</p>	<p>Article 15</p> <p>Resolutions on proposal at a board meeting shall, unless otherwise provided by <u>these Rules of Procedure</u> or the Company Act, be adopted with the attendance of a majority of the directors and the consent of a majority of the directors present.</p> <p>Paragraphs 2 to 5 are Omitted</p>	<p>The text was amended in accordance with regulations.</p>

<p>Article 17</p> <p>Minutes shall be prepared for Company's the board meetings, and such minutes shall contain a detailed record of the following:</p> <p>Subparagraphs 1 to 9 of Paragraph 1 were omitted.</p> <p>Resolutions adopted at a board meeting shall, in any of the following circumstances, be recorded in the minutes and, in addition, filed and announced on the Market Observation Post System designated by the Financial Supervisory Commission within two days after the date of the board meeting:</p> <ol style="list-style-type: none"> 1. An independent director has expressed an objection or reservation, and such objection or reservation has been recorded or stated in writing. 2. A matter has not been passed by the Company's Audit Committee, <u>but approved</u> by a vote of two-thirds or more of all directors. <p>The board of directors' attendance register forms part of the minutes and must be properly preserved for the duration of the Company's existence.</p> <p>The minutes must be signed or stamped by the chairperson and the recorder, distributed to all directors within twenty days after the meeting, and included in the Company's important records, where <u>they shall be properly preserved for the duration of the Company's existence.</u></p> <p>(The remainder was omitted.)</p>	<p>Article 17</p> <p>Minutes shall be prepared for the Company's board meeting, and such minutes shall contain a detailed record of the following:</p> <p>Subparagraphs 1 to 9 of Paragraph 1 were omitted.</p> <p>Resolutions adopted at a board meeting shall, in any of the following circumstances, be recorded in the minutes and, in addition, filed and announced on the Market Observation Post System designated by the Financial Supervisory Commission within two days after the date of the board meeting:</p> <ol style="list-style-type: none"> 1. An independent director has expressed an objection or reservation, and such objection or reservation has been recorded or stated in writing. 2. For companies that <u>have established an audit committee</u>, matters not approved by the audit committee may be approved <u>if</u> supported by at least two-thirds of all directors. <p>The attendance register of the board meeting is part of the minutes and must be retained permanently.</p> <p>The minutes must be signed or stamped by the chairperson and the recorder, distributed to all directors within twenty days after the meeting, and included in the Company's important records, where they shall be properly preserved <u>in perpetuity</u> for the duration of the Company's existence.</p> <p>(The remainder was omitted.)</p>	<p>This article was amended with minor editorial revision in accordance with regulations.</p>
---	---	---

<p>Article 18</p> <p>The process of all of the Company’s board meetings shall be fully recorded by audio or video for evidentiary purposes, and such recordings shall be preserved for at least five years; the retention may be conducted electronically.</p> <p>If litigation arises regarding a resolution passed by the Board of Directors before the expiration of the preservation period specified in the preceding paragraph, the relevant audio or video recordings shall continue to be preserved until the litigation is concluded.</p> <p>For meetings conducted via video conference, the <u>video and audio recordings shall constitute part of the meeting minutes and must be properly preserved for the duration of the Company’s existence.</u></p>	<p>Article 18</p> <p>The Company shall fully recorded all board meetings by audio or video for evidentiary purposes, and such recordings shall be preserved for at least five years; the retention may be conducted electronically.</p> <p>If litigation arises regarding a resolution passed by the Board of Directors before the preservation period specified in the preceding paragraph has expired, the relevant audio or video recordings shall continue to be preserved, and the provisions of the preceding paragraph shall not apply.</p> <p>Where a board meeting is conducted via video conference, <u>the audio and video recordings of such meetings shall constitute part of the minutes and shall be preserved permanently.</u></p>	<p>This article was amended with minor editorial revision in accordance with regulations.</p>
<p>Article 21</p> <p>These Rules of Procedure were adopted on March 10, 2011.</p> <p>.....</p> <p>The fourth amendment was made on May 5, 2012, the fifth amendment was made on May 5, 2023, the sixth amendment was made on May 2, 2024, and the seventh amendment was made on April 29, 2026.</p>	<p>Article 21</p> <p>These Rules of Procedure were adopted on March 10, 2011.</p> <p>.....</p> <p>The fourth amendment was made on May 5, 2012, the fifth amendment was made on May 5, 2023, and the sixth amendment was made on May 2, 2024,</p>	

Attachment 5

Dilution of the Company's Equity Interest in Its Subsidiary, Sanfu Biomedical Co., Ltd.

Date of Share Release	2026/01/26
Reason for Share Dilution	Cash capital increase
Issuance (Transfer) Price	NT\$ 25
Date of Approval by the Company's Audit Committee	2025/9/12 and 2025/10/31
Date of Approval by the Company's Board of Directors	2025/9/12 and 2025/10/31
Date of Approval by the Company's Shareholders' Meeting	2025/10/31
Shareholders' Meeting	N/A
Acquirers	15,000,000 shares
Total Number of Shares Issued (Transferred)	89.59%
Shareholding Ratio of the Company Before Issuance (Transfer)	57.59%
Shareholding Ratio of the Company After Issuance (Transfer)	Accountants were requested to issue an opinion on the reasonableness of the offering price.
Basis for Share Release Price Valuation	Without prejudice to the rights of existing shareholders
Impact on Shareholders' Equity	The Company's reduction of its shareholding in its subsidiary BioPhenix Co., Ltd. (hereinafter referred to as BioPhenix) by more than 10% is primarily due to the fact that in this capital increase by BioPhenix, 15% of the newly issued shares were subscribed by employees. The Company has waived its preemptive right as an existing shareholder in this capital increase, and all existing shareholders subscribed in proportion to their shareholdings. Any unsubscribed shares were subscribed by investors who have contributed to the operation and development of BioPhenix without prejudice to the rights and interests of existing shareholders. BioPhenix has commissioned an independent expert to issue an opinion on the reasonableness of the issuance price and its impact on the Company's shareholders' rights and interests in this capital increase.

Attachment 6

San Fu Chemical Co., Ltd. Rules of Procedure for Shareholders' Meetings (Comparative Table of Certain Current and Amended Articles)

Amended Articles	Current Articles	Explanation
<p>Article 3 (Notice of Convening and Holding Shareholders' Meetings) Paragraph 1 was omitted.</p> <p><u>When the Company convenes a video conference shareholders' meeting, unless otherwise provided in the Regulations Governing the Administration of Shareholder Services for Public Companies, such meeting must be provided for in the Articles of Incorporation and approved by a resolution of the Board of Directors; furthermore, the video conference shareholders' meeting may only be held pursuant to a resolution of the Board of Directors passed with the attendance of at least two-thirds of the directors and the approval of a majority of the directors present.</u> Paragraph 3 was omitted.</p> <p>The Company shall, no later than 30 days prior to a general shareholders' meeting or 15 days prior to an extraordinary shareholders' meeting, prepare electronic files containing the notice of the shareholders' meeting, proxy forms, the acknowledgments, discussions, and the subject and explanation materials of proposals, the <u>shareholders' meeting proceedings handbook, and supplementary materials for all agenda items</u> (including resolutions for approval, discussion, and the election or removal of directors), , and submit them to the Market Observation Post System.</p> <p><u>The Company shall prepare the meeting proceedings manual and supplementary materials for the shareholders' meeting 15 days prior</u></p>	<p>Article 3 (Notice of Convening and Holding Shareholders' Meetings) Paragraph 1 was omitted.</p> <p>The original Paragraph 2 was omitted.</p> <p>The Company shall, no later than 30 days prior to a general shareholders' meeting or 15 days prior to an extraordinary shareholders' meeting, prepare electronic files containing the notice of the shareholders' meeting, proxy forms, and the subject and explanatory materials for all matters to be considered, including the resolutions for approval, discussion, and the election or dismissal of directors and <u>independent directors</u>, and submit them to the Market Observation Post System.</p> <p><u>The shareholders' meeting proceedings manual and supplementary materials shall be prepared in electronic format and sent to the Market Observation Post System 21 days before the general shareholders' meeting or 15 days before the extraordinary shareholders' meeting. However, if the Company's paid-in capital reaches NT\$10 billion or more as of the end of the most recent fiscal year, or if the combined shareholding ratio of foreign and</u></p>	<p>1. These articles have been amended in accordance with Article 172-2 of the Company Act</p> <p>2. Pursuant to Article 6 of the "Regulations Governing Content and Compliance Requirements for Shareholders' Meeting Agenda Handbooks of Public Companies", the deadline for listed companies to transmit electronic files containing the proceedings manual and other relevant information has been extended to 30 days prior to the shareholders' meeting of shareholders.</p> <p>3. Accordingly, a new Paragraph 2 has been added, and the original Paragraphs 2 to 11 have been renumbered and amended.</p>

<p>to the meeting, so that shareholders may request them at any time, and these materials shall be displayed at the Company and the professional shareholding agents appointed by the Company.</p> <p>Paragraphs 5 to 6 were omitted.</p> <p>The appointment or removal of directors, amendments to the Articles of Incorporation, capital reduction, applications to cease public offering, approval of directors' engagement in competing with the Company, capitalization of retained earnings, capitalization of statutory reserves, dissolution of the Company, merger, division, or matters specified in the various subparagraphs of Article 185, Paragraph 1 of the Company Act, <u>Articles 26-1 and 43-6 of the Securities and Exchange Act, and Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers</u> shall be listed in the notice of meeting along with a description of their main contents and may not be proposed as a motion at the meeting.</p> <p>Paragraph 8 was omitted.</p> <p>A shareholder holding one percent</p>	<p><u>Mainland Chinese investors recorded in the shareholder register at the shareholders' meeting held in the most recent fiscal year reaches 30% or more, the Company shall complete the transmission of the aforementioned electronic file 30 days before the shareholders' meeting.</u> Fifteen days prior to the shareholders' meeting, the meeting proceedings manual and supplementary materials shall be prepared for shareholders to access at any time and shall be displayed at the Company and the professional shareholding agents appointed by the Company.</p> <p>The original Paragraphs 4 to 6 were omitted.</p> <p>The appointment or removal of directors, amendments to the Articles of Incorporation, capital reduction, applications to cease public offering, approval of directors' engagement in competing businesses, capitalization of retained earnings, capitalization of statutory reserves, dissolution of the Company, merger, division, or matters specified in the various subparagraphs of Article 185, Paragraph 1 of the Company Act shall be listed in the notice of meeting along with a description of their main contents and may not be proposed as a motion at the meeting.</p> <p>The original Paragraph 7 was omitted.</p> <p>A shareholder holding one percent or more of the total issued shares may submit one proposal to the Company for consideration at the general shareholders' meeting; if more than one proposal is</p>	
--	---	--

<p>or more of the total issued shares may submit one proposal to the Company for consideration at the general shareholders' meeting; if more than one proposal is submitted, none of them shall be included in the agenda. Furthermore, if a proposal submitted by a shareholder falls under any of the circumstances specified in Article 172-1, Paragraph 4 of the Company Act, the Board of Directors may exclude it from the agenda. Shareholders <u>may submit advisory proposals</u> to urge the Company to promote the public interest or fulfill its social responsibilities. Such proposals shall be limited to one per shareholder in accordance with the relevant provisions of Article 172-1 of the Company Act; any proposals exceeding this limit shall not be included in the agenda.</p> <p>Paragraphs 10~12 were omitted.</p>	<p>submitted, none of them shall be included in the agenda. <u>However, if a shareholder's proposal is intended</u> to urge the Company to promote the public interest or fulfill its social responsibilities, the Board of Directors may still include it on the agenda. Furthermore, if a shareholder proposal falls under any of the circumstances specified in Article 172-1, Paragraph 4 of the Company Act, the Board of Directors may exclude it from the agenda.</p> <p>The original Paragraphs 9~11 were omitted.</p>	
<p>Article 4 (Proxy Attendance at Shareholders' Meetings and Authorization)</p> <p>Paragraphs 1~2 were omitted.</p> <p>If a shareholder who has submitted a proxy form to the Company wishes to attend the shareholders' meeting in person or <u>to exercise his or her voting rights in writing or electronically</u>, he or she must notify the Company in writing for the revocation of the proxy at least two days prior to the meeting. If the revocation is made after this deadline, the voting rights shall be exercised by the proxy as originally designated.</p> <p>Paragraphs below were omitted.</p>	<p>Article 4 (Proxy Attendance at Shareholders' Meetings and Authorization)</p> <p>Paragraphs 1~2 were omitted.</p> <p>If a shareholder who has submitted a proxy form to the Company wishes to attend the shareholders' meeting in person, he or she must notify the Company in writing of the revocation of the proxy <u>no later</u> than two days prior to the meeting. If the revocation is received after this deadline, the voting rights shall be exercised by the proxy holder.</p> <p>Paragraphs below were omitted.</p>	<p>This article was amended in accordance with regulations.</p>

<p>Article 6-1 (Convening a Videoconference Shareholders' Meetings Matters to be Included in the Meeting Notice)</p> <p>When the Company convenes video conference shareholders' meetings, the notice of the meeting shall specify the following matters:</p> <ol style="list-style-type: none"> 1. The method for shareholders to participate in the videoconference meeting and exercise their rights. 2. The procedures to be followed in the event that the video conference platform or the ability to participate via videoconference is disrupted due to natural disasters, unforeseen events, or other force majeure circumstances, which shall include, at least following matters: Items 1 to 4 of Subparagraph 2 of Paragraph 1 were omitted. 3. When convening a video conference shareholders' meeting, the Company shall specify appropriate alternative measures for any shareholders who have difficulty participating in the meeting via video conference. <u>Except as provided in Article 44-9, Paragraph 6 of the Regulations Governing the Administration of Shareholder Services of Public Companies, the Company shall provide shareholders with the necessary equipment and assistance for online access, and shall specify the period during which shareholders may submit requests to the Company, as well as other relevant matters to be noted.</u> 	<p>Article 6-1 (Convening a Videoconference Shareholders' Meeting: Matters to be Included in the Meeting Notice)</p> <p>When the Company convenes video conference shareholders' meetings, the notice of the meeting shall specify the following matters:</p> <ol style="list-style-type: none"> 1. The method for shareholders to participate in the videoconference meeting and exercise their rights. 2. The procedures to be followed in the event that the video conference platform or the ability to participate via videoconference is disrupted due to natural disasters, unforeseen events, or other force majeure circumstances, which shall include, at least following matters: Items 1 to 4 of Subparagraph 2 of Paragraph 1 were omitted. 3. When convening a video conference shareholders' meeting, the Company shall specify appropriate alternative measures for any shareholders who have difficulty participating in the meeting via video conference. 	<p>This amendment was made to clarify that public companies may conduct shareholders' meetings with the assistance of video conferencing, to specify the procedures for providing digital assistance to shareholders, and to set forth the period during which shareholders may submit requests to the Company, as well as other relevant matters to be noted.</p>
<p>Article 22 (Handling digital discrepancies)</p> <p>When the Company convenes a video conference shareholders' meeting, it shall provide</p>	<p>Article 22 (Handling digital discrepancies)</p> <p>When the Company convenes a video conference shareholders' meeting, it shall provide</p>	<p>This amendment was made to clarify that public companies may conduct shareholder meetings with the</p>

<p>appropriate alternative arrangements for shareholders who have difficulty attending the meeting via video conference.</p> <p><u>Except as provided in Article 44-9, Paragraph 6 of the Regulations Governing the Administration of Shareholder Services for Public Companies, the Company shall provide shareholders with internet access and necessary assistance, and specify the period during which shareholders may submit requests to the Company, as well as other relevant matters to be noted.</u></p>	<p>appropriate alternative arrangements for shareholders who have difficulty attending the meeting via video conference.</p>	<p>assistance of video conferencing, to specify the procedures for providing digital assistance to shareholders, and to set forth the period during which shareholders may submit requests to the Company, as well as other relevant matters to be noted.</p>
<p>Article 24 Supplementary Provisions</p> <p>This procedure was established on April 18, 2011.</p> <p>.....</p> <p>The seventh amendment was made on July 5, 2021. The eighth amendment was made on June 17, 2022. <u>The ninth amendment was made on June 12, 2026.</u></p>	<p>Article 24 Supplementary Provisions</p> <p>This procedure was established on April 18, 2011.</p> <p>.....</p> <p>The seventh amendment was made on July 5, 2021. The eighth amendment was made on June 17, 2022.</p>	<p>The amendment dates were recorded.</p>